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Abstract
Objectives To analyse the development of MRI-guided
vacuum-assisted biopsy (VAB) in Switzerland and to compare
the procedure with stereotactically guided and ultrasound-
guided VAB.
Methods We performed a retrospective analysis of VABs be-
tween 2009 and 2011. A total of 9,113 VABs were performed.
Of these, 557 were MRI guided.
Results MRI-guided VAB showed the highest growth rate
(97 %) of all three procedures. The technical success rates
for MRI-guided, stereotactically guided and ultrasound-
guided VAB were 98.4 % (548/557), 99.1 % (5,904/5,960)
and 99.6 % (2,585/2,596), respectively. There were no signif-
icant differences (P=0.12) between the MRI-guided and the
stereotactically guided procedures. The technical success rate
for ultrasound-guided VAB was significantly higher than that
for MRI-guided VAB (P< 0.001). There were no complica-
tions using MRI-guided VAB requiring open surgery. The
malignancy diagnosis rate for MRI-guided VAB was similar
to that for stereotactically guided VAB (P= 0.35).
Conclusion MRI-guided VAB is a safe and accurate proce-
dure that provides insight into clinical breast findings.
Key points
• Three vacuum-assisted breast biopsy (VAB) procedures
were compared.
• Technical success rates were high for all three VAB
procedures.
• Medical complications were relatively low using all three
VAB procedures.
• The use of MRI-guided vacuum-assisted breast biopsy is
growing.
Keywords Breast carcinoma . Vacuum-assisted biopsy .
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Introduction
Vacuum-assisted biopsy (VAB) devices came onto the market
in the mid-1990s with the goal of eliminating the sampling
difficulties associated with core needle biopsy. The larger
tissue volume resulting from VAB facilitates removal of
microcalcifications and is associated with less frequent under-
diagnosis of malignancies [1, 2]. VAB is currently recom-
mended for stereotactic and MRI-guided interventions [3, 4].
Ultrasound-guided VAB is not generally indicated, because
the less expensive core biopsy procedure frequently achieves
the same objective [5]. Ultrasound-guided VAB might be
indicated as a therapeutic procedure for histology proven
benign lesions in selected situations.
Stereotactically guided VABs have reduced the repeat-
biopsy rate (9 % versus 14.9 %) and the percentage of unusable
samples (0 % versus 9.5 %) [6]. VAB also leads to a higher
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diagnostic yield and greater accuracy in MRI-guided proce-
dures [4] and permits the retention of the needle in the breast
during cylinder collection, resulting in a lower risk of needle
dislocation in comparison to core needle biopsy. Another ben-
efit of VAB is the possibility of direct aspiration of blood in the
event of bleeding complications.
Several indications for MRI of the breast, including screen-
ing the high-risk population, have been recommended by the
American College of Radiology (ACR) [7]. Because of the
method’s high sensitivity, MRI can detect suspected breast
malignancies that usually escape clinical, ultrasound and
mammographic detection.
A result of the wide use of MRI in breast diagnostics is an
increase in incidental findings. Because of the high sensitivity
and lower specificity of breast MRI, it is imperative that these
findings be histologically assessed before any surgical inter-
vention [8–10]. MRI-guided VAB is indicated for MRI find-
ings from patients in BI-RADS categories 4 and 5, as well as
BI-RADS 3 in individual cases (e.g. for high-risk patients or
after breast-conserving treatment) without correlating findings
on mammography or ultrasound [11]. Depending on patient
selection, the correlation rate of MRI findings with second-
look ultrasound ranges from 23 to 83 % [12–15]. In positive
ultrasound correlation of the findings, ultrasound intervention
is preferable to MRI-guided intervention because it is simpler,
faster and more cost-effective than MRI. However, MRI-
guided VAB is a safe, highly accurate method which rarely
leads to complications [16].
In Switzerland, as a legal requirement stipulated by the
Swiss Federal Office of Public Health and a prerequisite for
reimbursement, all data of all minimally invasive breast biop-
sies (MIBB) have to be entered in a central database
The purpose of our study was to analyse the development
of MRI-guided VAB and to compare the procedure with
stereotactically guided and ultrasound-guided VAB in
Switzerland. The study also examined the technical success
rate, the complication rates and the completeness and usability
of histological results of MRI-guided VAB compared with the
other two procedures.
Materials and methods
Origin of the data
Data from all 53 MIBB centres in Switzerland were collected
by the image-guided MIBB Working Group of the Swiss
Society of Senology (SGS) [5], on behalf of the Swiss
Federal Office of Public Health (Bundesamt für Gesundheit
[BAG]). According to the quality guidelines of the MIBB
group, the operator for VAB procedures must be a specialist
in radiology, gynaecology, obstetrics or surgery. Before being
allowed to operate independently, the operator must complete a
workshop with successful interventions on a phantom and five
supervised interventions when the method is established at their
institute or 20 interventions under supervision when themethod
is newly introduced at their institution. For maintenance of
qualifications, each operator must perform at least 12 interven-
tions per year, with a minimum of 20 interventions per institu-
tion per year. Using an 11-G needle or bigger depending of the
size of the lesion at least 12 samples should be taken [5].
Adjumed Services AG (Zurich, Switzerland) provides an
online questionnaire (www.mibb.ch) that has to be completed
by the institutions. Accreditation as an MIBB operator and
complete data collection are prerequisites for reimbursement
by the health insurance companies. Patients were informed
before a vacuum biopsy that the collected data would be made
available in anonymised form for further data analysis and
gave written informed consent [17]. The identities of patients,
surgeons and institutions could not be ascertained. The
responsible ethics committee approved this data-sharing plan.
Raw data processing
This study was based on 9,113 records of VABs of the breast
with biopsies performed in Switzerland between 2009 and
2011. The full data set contains 9,153 records and will be used
in a second study focusing on histopathological B3 lesions. In
this study we excluded 40 records that lacked information
regarding the biopsy method. All mammographically guided
biopsies performed using either a stereotactic table with the
patient in a prone position (n =5,340) or in an “upright” device
with the patient in a seated position (n =564) were included in
the stereotactically guided VAB method group. A distinction
between these two procedural variations was maintained only
for the analysis of complications and the chronological devel-
opment of the biopsy methods. During the analysis of the
indications, complications and histological results, multiple
answers were converted as often as possible into single
answers.
With regard to multiple answers for histological diagnoses,
the degree of malignancy was arranged in descending order
and the most degenerate diagnosis was retained.
A positive family history was recorded when a patient’s
mother, sister or daughter (1st degree of kinship) had a posi-
tive history of breast carcinoma.
If there was no information or unclear information provided
for the individually analysed data types, this was interpreted as
a missing answer and the data were excluded from the respec-
tive analysis.
Implementation of image-guided VAB
There are many reports in the literature relating to the techni-
cal implementation of image-guided VAB [2, 18]. Figure 1
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shows images of MRI-guided vacuum biopsies from a patient
who had negative second-look ultrasound.
Histological evaluation
Tissue sample preparation was carried out according to the
quality standards of the Swiss Society of Pathology
(Schweizer Gesellschaft für Pathologie (SGPath)) [19].
Statistical methods
Categorical variables of the groups were compared using the
chi-squared test. IBM SPSS Statistics version 20 (SPSS Inc.,
Chicago, IL, USA)was used for statistical analyses. Values of P
<0.05 were considered statistically significant. The Bonferroni
correction was used when single VABmethods were compared.
Because MRI-guided VAB was compared with the other two
VAB methods (stereotactically guided and ultrasound-guided
VAB), a P value of less than 0.025 was considered statistically
significant. In the analysis of the complication rates, the three
VAB methods (using a stereotactic table, an upright device
and ultrasound) were compared to the MRI-guided VAB
method (P <0.017 was considered statistically significant).
Sensitivity, specificity, negative (NPV) and positive (PPV)
predictive values were presented as percentages with 95 %
Wilson confidence intervals (CI).
Results
VAB developments in Switzerland
Of the 9,113 VABs, 557 (6 %) were performed using MRI
guidance, 5,391 (59 %) using stereotactic guidance (by means
of a dedicated stereotactic table), 569 (6 %) using a stereotac-
tic upright device and 2,596 (28 %) using ultrasound guid-
ance. Developments in the use of VAB techniques are shown
in Fig. 2.
VAB technical success rates
Seventy six VABs were unsuccessful because of no histology in
69 (MRI 0.9 % [5/557], stereotactically 0.9 % [53/5,960],
ultrasound 0.4 % [11/2,596]) and no collection of biopsy
Fig. 1 A 77-year-old female patient with diffuse hardening of the right
breast showing infiltration of an invasive lobular, predominantly pleo-
morphic breast carcinoma. a–d Mammography images showed bilateral
benign microcalcifications and slight volume asymmetry on the left side,
as well as densification of the interstitial structures on the right side; BI-
RADS 3 right side and BI-RADS 2 left side. e , f T1-weighted MRI and
post-contrast subtraction (left side): an incidental T1-hypointense (e)
stellate lesion (arrows) and on the first subtraction early contrast-en-
hanced image (f) (BI-RADS 4). g T1 biopsy image. h Histological
section showing invasive lobular, predominantly pleomorphic breast
carcinoma (haematoxylin and eosin; magnification×100) (doi: 10.1594/
ecr2013/C-0554)
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material was possible in 7 cases (MRI 0.7% [4/557], stereotactic
0.05 % [3/5,960], ultrasound 0 % [0/2,596]) leading to an
overall success rate of 99.2 % (9,037/9,113). The technical
success rate for MRI-guided VAB was 98.4 % (548/557),
99.1 % for stereotactically guided VAB (5,904/5,960) and
99.6 % (2,585/2,596) for ultrasound-guided VAB. There was
no significant difference (P= 0.12) in the technical success rates
between the MRI-guided procedures and the stereotactic proce-
dures. As expected this rate for ultrasound guidance, with its
benefits of real-time imaging, was significantly higher than that
for MRI (P< 0.001). The 9,037 successfully implemented
VABs formed the basis for further analyses.
Family and carcinoma history
A family history of breast cancer was positive in 2,014 (22 %)
cases (Table 1). There was no significant difference in positive
family history between the MRI-guided and stereotactically
guided VAB procedures (P= 0.23). The occurrence of a positive
family history was more frequent in patients who underwent
Fig. 2 Developments in image-
guided vacuum-assisted biopsy
(VAB) in Switzerland between
2009 and 2011. a Total number of
VABs performed. b Number of
MRI-guided VABs performed. c
The number of VABs undertaken
using a stereotaxis table. d
Number of VABs undertaken
using an upright device. e
Number of ultrasound-guided
VABs. The percentage change in
image-guided VAB usage (red
lines) is also shown (doi: 10.
1594/ecr2013/C-0554)
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MRI-guided VAB than in those who underwent ultrasound-
guided VAB (P< 0.001).
A positive personal history of breast carcinomawas present
in a total of 1,227/9,037 (14 %) of the biopsy cases
(Table 1).The MRI-guided procedure was used in a signifi-
cantly higher proportion of these patients than the stereotacti-
cally guided (P< 0.001) or ultrasound-guided (P< 0.001)
procedures.
Indications
No specific indication was listed in 107/9,037 (1 %) of the
cases; this was true in 18/548 of the MRI-guided VAB cases,
in 8/5,904 of the stereotactically guided VAB cases and in 81/
2,585 of the ultrasound-guided VAB cases.
Seventy nine per cent (421/530) of the findings clarified
using MRI-guided VAB were detected by MRI only. The
rationale for the intervention was based purely on mammo-
graphic findings in 94 % (5,527/5,896) of the stereotactically
guided VAB cases and purely on ultrasound findings in 69 %
(1,718/2,504) of the ultrasound-guided VAB cases
Clip insertion
In MRI-guided VAB a clip marker was used in 84 % of cases
(460/548), in stereotactically guided VAB in 86 % of cases
(5,091/5,904) and in ultrasound-guided VAB in 23 % (603/
2,585) of cases. There was no significant difference in clip
marker usage between the MRI-guided and stereotactically
guided VAB procedures, but a significantly higher number of
clip markers were used in MRI-guided procedures than in
ultrasound-guided procedures (P <0.001).
Complications
The complication rate of MRI-guided VAB was compared to
VAB using stereotaxis table, upright device and ultrasound.
Complications were divided into medical (haemorrhages
with or without open revision and infection) and non-medical
(technical complications, missed lesions and lesion inaccessi-
bility). No specific complications were reported in 52/9,037 of
cases. Terminated intervention was reported in 19/9,037 cases
without stating the medical or technical grounds on which the
decision was based.
In total, 8,966 records were available for evaluation of the
complication rate, and complications were recorded in 6 %
(511/8,966). The distribution of the complications is shown in
Table 2.
The overall complication rates for the VAB procedure
using a stereotaxis table (P= 0.08) or using the upright device
(P= 0.02) were not significantly different from that for the
MRI-guided procedure. The overall complication rate for
ultrasound-guided VAB was significantly lower (P< 0.001)
relative to that for MRI-guided VAB.
There was no case of bleeding requiring surgical interven-
tion by MRI-guided VAB.
Histological evaluation
Information on the histological assessment of the vacuum
biopsy cylinders was unavailable in 54/9,037 cases. For the
entire study population, the material obtained was specified by
the pathologist as representative in 97.6 %: samples from
MRI-guided, stereotactically guided and ultrasound-guided
VABs were representative in 96.6 % (512/530), 97.3 %
(5,724/5,884) and 98.5 % (2,530/2,569) of cases, respectively.
Because the histological findings for the VABs were spec-
ified as “other” in 175/9,037 (2 %) of cases, a distinction
between malignant, “high-risk” or benign histology was im-
possible and these data were excluded from the malignancy
rate analysis.
For the entire study population, VAB revealed malignant
lesions in 1,853/8,862 cases (21 %; 37 % invasive carcinoma
and 63 % DCIS), benign lesions in 5,524/8,862 cases (62 %)
and high-risk lesions in 1,485/8,862 cases (17 %) (Table 3).
The rate of malignancy in stereotactically guided VABs was
not significantly different from that for MRI-guided VAB (P
= 0.35), but the malignancy rate for the MRI-guided proce-
dure was significantly higher than that for the ultrasound-
guided procedure (P=0.001).
Histology of subsequent surgical excisions
Of the 8,862 VAB samples with known histological results, a
total of 2,434 (27%) lesions were further clarified bymeans of
subsequent surgery and histological analysis of the tissue
samples obtained. No histological data from the surgery were
available in 131 cases. Ninety per cent (1,660/1,853) of the
malignant lesions, 5 % (255/5,524) of the benign lesions and
35 % (519/1,485) of the high-risk or B3 lesions were surgi-
cally excised.
The rates of upgrade to malignant disease after histological
analysis of open surgical excision samples for the various
image-guided VAB procedures are listed in Table 4. The
number of false negatives was 3 %, 1 % and 0.4 % for the
MRI-guided, stereotactically guided and ultrasound-guided
VAB procedures, respectively. Benign and high-risk lesions
Table 1 Patient carcinoma history
History MRI Stereotactic Ultrasound
Family 26 % (144/548) 24 % (1,416/5,904) 18 % (454/2,585)
Personal 41 % (227/548) 13 % (771/5,904) 9 % (229/2,585)
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were upgraded at a significantly higher rate after open surgical
excision for the MRI-guided procedure than was the case for
the stereotactically guided (P< 0.001) and the ultrasound-
guided (P< 0.001) procedures.
Surgical specimens of the 1,853 malignant lesions no lon-
ger revealed malignancy in 115 cases (6 %) post-VAB; full
removal of the lesion during VABwas thus assumed. Absence
of malignancy in the surgical specimens occurred in 3 % (4/
137) of cases after MRI-guided VAB, in 7 % (99/1,408) after
stereotactically guided VAB and in 4 % (12/308) after
ultrasound-guided VAB.
Sensitivity of VAB
In the calculation of the sensitivity and specificity, as well as
the positive and negative predictive values (Table 5), the
assumption of complete removal of the lesion during VAB
in the event of missing evidence of malignancy in the surgical
specimen was not considered.
Discussion
To our knowledge, the present study is the largest comparative
study involving VABs with MRI, stereotactic and ultrasound
guidance to date. We have shown that in Switzerland through-
out the study period the number of MRI-guided VABs rose
significantly by 97 %, whereas the number of the other two
image-guided VAB techniques performed remained mostly
constant. The increase in the number of MRI-guided vacuum
biopsies is not due to any decrease in ultrasound-guided biop-
sies. An “MRI only” finding was the indication for MRI-
guided biopsy in 79 % of the cases and an “ultrasound only”
finding was the indication for 69 % of ultrasound-guided
biopsies. The increase in MRI-guided VABs can be explained
by the increasing use of MRI in breast diagnostics, and the
resultant increasing number of findings requiring clarification.
The technical success rate forMRI-guided VABwas slight-
ly lower than that for the stereotactically guided and
ultrasound-guided procedures, most likely because more com-
plex technical requirements and longer intervention periods
Table 3 Malignancy rate by bi-
opsy technique MRI Stereotactic Ultrasound
Malignant lesions Overall rate
26 % (137/527) 24 % (1,408/5,822) 12 % (308/2,513)
Invasive carcinoma rate
64 % (88/137) 25 % (359/1,408) 78 % (240/308)
DCIS rate
36 % (49/137) 75 % (1,049/1,408) 22 % (68/308)
Benign lesions 54 % (283/527) 59 % (3,407/5,822) 73 % (1,834/2,513)
High-risk lesions 20 % (107/527) 17 % (1,007/5,882) 15 % (371/2,513)
Table 2 Overall, medical and
non-medical complications dur-
ing vacuum-assisted biopsies
(VABs) performed under the
guidance of MRI, a stereotactic
table, a stereotactic upright device
and ultrasound
Complications VAB procedure






Overall 44 (8 %) 328 (6 %) 26 (5 %) 113 (4 %)
Total medical 38 (7 %) 252 (4.7 %) 20 (3.7 %) 102 (4.0 %)
Haemorrhage without open revision 38 (7 %) 245 (4.6 %) 19 (3.5 %) 98 (3.8 %)
Haemorrhage with open revision 0 (0 %) 5 (0.1 %) 1 (0.2 %) 3 (0.1 %)
Infection 0 (0 %) 2 (0.04 %) 0 (0 %) 1 (0.04 %)
Total non-medical 5 (1 %) 70 (1.3 %) 4 (0.7 %) 11 (0.4 %)
Technical complications 3 (0.6 %) 33 (0.6 %) 2 (0.4 %) 9 (0.4 %)
Lesion missed 2 (0.4 %) 30 (0.6 %) 2 (0.4 %) 1 (0.04 %)
Inaccessible lesions 0 (0 %) 7 (0.1 %) 0 (0 %) 1 (0.04 %)
Combined (medical & non-medical) 1 (0.2 %) 6 (0.1 %) 2 (0.2 %) 0 (0 %)
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are involved in the use of MRI-guided VAB. The technical
success rates for image-guided VABs were comparable with
or superior to those previously reported [13, 20–29].
There is a lack of significant difference in family histories
between the MRI-guided and stereotactically guided proce-
dures. We would have expected a higher percentage of pa-
tients with positive family history for the MRI-guided proce-
dure. However, the lack of difference is probably explained by
the fact that MRI, although recommended by the ACR guide-
lines, has not yet been established in Switzerland as the
screening method for high-risk population [7].
Because the indication for diagnostic MRI includes screen-
ing for contralateral extension in newly diagnosed breast
cancer, determination of the spread of the disease or follow-up
examinations [7], patients undergoing MRI-guided biopsy
have a higher have a higher rate of previous breast cancer.
The MRI-guided VAB shows, despite higher technical
requirements, a comparable complication rate compared
to VAB under stereotactic guidance. The majority of
complications of MRI-guided VAB were haemorrhages,
none requiring surgical intervention. Therefore it is a safe
procedure.
The total complication rate of MRI-guided VAB lies within
the published range of complication rates (2–14 %) [16, 23,
26–28, 30].
No significant difference in the rates of diagnosis of ma-
lignancy between MRI-guided and stereotactically guided
procedures was found. The rate of diagnosis of malignancy
using ultrasound-guided VABwas significantly lower because
of the lack of distinction between diagnostic and therapeutic
ultrasound-guided VABs and the generally lower pretest like-
lihood of malignancy of the BI-RADS 3 lesions usually
selected for ultrasound-guided VAB. The rate of malignancy
detection achieved using MRI-guided VAB corresponds with
those (22–33 %) previously reported [4, 22, 24, 28, 30–32].
The upgrade rate of histologically benign and high-risk
lesions to malignancies for the MRI-guided VAB [31] was
significantly higher than that for the stereotactically guided
group. This leads to a lower sensitivity and NPVof the MRI-
guided VAB in comparison to the stereotactically guided
procedure, whereby the MRI-guided VAB shows a higher
specificity and PPV. Both the specificity and PPV of MRI-
guided VAB have been reported to be 100 % [20, 27].
These parameters had lower values in the current study
because although complete removal of the lesion by VAB
prior surgical excision might be an explanation in the
event of missing proof of malignancy in the final speci-
men, we did not include this option in the calculation. The
sensitivity of MRI-guided VAB has been reported to be 92.3–
93 % and the NPV 93–96.7 % [20, 27]. It was not possible to
verify whether the biopsied lesion correlated with the excised
lesion in all cases. Although in most cases (84 %) of MRI-
guided VAB the biopsy site was marked by a clip and we
expect that the clip was part of the resected tissue, it is
conceivable that the histology of the surgical specimen, e.g.
multifocal lesions, did not relate to the same lesion as the
histology of the VAB specimen; thus, in this respect the
analysis is limited. Therefore, especially in MRI-guided
VAB, it is necessary to mark the biopsy site for surgical
correlation or follow-up with a clip and, in cases of benign
results and mismatch with the imaging findings, to discuss
the possibility of a repeat biopsy.
Another limiting factor of our study was that the data were
recorded by the individual MIBB centres in Switzerland,
making errors in data input conceivable. On the other hand,
because of the large number of participating centres, a very
large amount of data was available for analysis, providing an
advantage over other studies with considerably smaller case
numbers.
In summary,MRI-guidedVAB is a safe, specific andwidely
accepted, growing procedure. As a result of a slightly lower
sensitivity, in cases with benign histology a re-evaluation
and potentially a repeat biopsy should be discussed if
findings persist or if there is a mismatch between histology
and imaging.
Table 5 Sensitivity by biopsy technique
MRI Stereotactic Ultrasound
Sensitivity 79.7 % (95 % CI 72.2–85.6 %) 91.5 % (95 % CI 89.9–93 %) 95.7 % (95 % CI 92.6–97.5 %)
Specificity 92.2 % (95 % CI 81.5–96.9 %) 81.9 % (95 % CI 78.4–84.9 %) 91.7 % (95 % CI 80–95.2 %)
PPV 96.5 % (95 % CI 91.3–98.6 %) 92.2 % (95 % CI 90.6–93.6 %) 95.7 % (95 % CI 92.6–97.5 %)
NPV 62.7 (95 % CI 51.4–72.7 %) 80.5 % (95 % CI 77–83.6 %) 91.7 % (95 % CI 80–95.2 %)
Table 4 Rate of upgrade to malignancy after open surgical excision for
the three image-guided VAB procedures based on histological analysis of
the VAB samples
Upgrade rate VAB procedure
MRI Stereotactic Ultrasound
Total 28/390 (7 %) 108/4,414 (2 %) 12/2,205 (1 %)
Benign 8/283 (3 %) 22/3,407 (1 %) 8 (0.4 %)
High-risk/B3 20/107 (19 %) 86/1,007 (9 %) 5/371 (0.2 %)
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